0000000000532137

AUTHOR

L Russo

showing 11 related works from this author

Concealed arrhythmogenic rigth ventricula cardiomyopathy: pathologic substrates and high resolution MRI

2004

researchProduct

La valutazione retinica mediante Tomografia a Coerenza Ottica (OCT) nel diabete mellito tipo 1.

2008

OCT diabete tipo 1
researchProduct

BRAFV600E mutation and timp-1 hyper-expression in classical variants of papillary thyroid carcinoma (PTC).

2009

PTC
researchProduct

No association between BRAFV660E and metalloproteinase activity in anaplastic thyroid cell lines

2008

Endocrinologia Metabolismo e NutrizioneRicerca e sviluppo sperimentale nel campo delle biotecnologieSettore MED/13 - Endocrinologia
researchProduct

Il c-peptide come marker principale nella storia naturale del Diabete di tipo 1: ruolo della funzione b-cellulare pancreatica nelle complicanze.

2004

c-peptide
researchProduct

VIGOR: Sviluppo geotermico nelle Regioni della Convergenza. Progetto VIGOR – Valutazione del Potenziale Geotermico delle Regioni della Convergenza, P…

2014

Geotermia Termini Imerese
researchProduct

Fine-Needle Aspiration (FNAB) Molecular Analysis for the Diagnosis of Papillary Thyroid Carcinoma through BRAFv600E mutation and RET/PTC rearrangement

2007

Objective: To evaluate BRAFV600E mutation on consecutive fine-needle aspiration biopsy (FNAB) specimens in order to assess FNAB’s usefulness in preoperative papillary thyroid carcinoma (PTC) diagnosis with the contemporaneous analysis of RET=PTC1 and RET=PTC3 rearrangements obtained from ex vivo thyroid nodules. Design: Thyroid FNABs from 156 subjects with nodules and 49 corresponding surgical samples were examined for the presence of BRAF mutation by real-time allele-specific polymerase chain reaction, confirmed with the use of a laser pressure catapulting system. Samples were also examined for RET=PTC rearrangements. The results were compared with the cytological diagnosis and histopathol…

AdultMaleProto-Oncogene Proteins B-rafPathologymedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismBiopsyBiopsy Fine-NeedlePapillarySettore MED/08 - Anatomia PatologicaRET/PTCSettore MED/13 - EndocrinologiaThyroid carcinomaCohort StudiesEndocrinologyPredictive Value of TestsBiopsyCarcinomamedicine80 and overHumansThyroid NeoplasmsAgedRET/PTC RearrangementAged 80 and overGene Rearrangementmedicine.diagnostic_testbusiness.industryCarcinomaProto-Oncogene Proteins c-retGene rearrangementMiddle Agedmedicine.diseaseCarcinoma PapillaryAdult; Aged; 80 and over; Amino Acid Substitution; Biopsy; Fine-Needle; Carcinoma; Papillary; Cohort Studies; Female; Gene Rearrangement; Humans; Male; Middle Aged; Predictive Value of Tests; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Thyroid NeoplasmsBrafBRAF V600EFine-needle aspirationAmino Acid SubstitutionMutation (genetic algorithm)Fine-NeedleFemalebusiness
researchProduct

Azione antalgica di Hydrogel nell'orbitopatia basedowiana

2007

La terapia dell'orbitopatia,nella fase acuta,si basa oltre che sulla correzione della turba endocrinologica,sulla protezione della cornea e sull'uso dei corticosteroidi ad alto dosaggio o di farmaci immunosoppressori o, in alternativa,sulla radioterapia orbitaria.Per attenuare la sintomatologia dolorosa,frequente nella fase acuta e che può inficiare la qualità della vita,data la componente flogistica,abbiamo voluto valutare gli effetti di una terapia antalgica mediante appliocazione sulla superficie palpebrale di un gel chirurgico criogenico decongestinante ( a contenuto di estratto di ananas più acido betaglicirretico),ad oggi utilizzato con risultati soddisfacenti in soggetti sottoposti a…

Settore MED/30 - Malattie Apparato VisivoOrbitopatia basedowiana (OB)American Thyroid Association MMI Hydrogel
researchProduct

BrafV600E mutation and hyperexpression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in papillary thyroid carcinoma

2009

Settore MED/06 - Oncologia MedicaTimp-1 braf thyroid carcinomaSettore MED/13 - Endocrinologia
researchProduct

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately …

2017

Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50–75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2–3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and…

MaleDiabetes and Metabolism ipoglycemic drugs cardiovascualr eventSettore MED/09 - Medicina Internaendocrine system diseasesIMPACTpioglitazone versus sulfonylureasEndocrinology Diabetes and MetabolismGLIMEPIRIDEDiabetes cardiovascular events metformin pioglitazone sulphonylureasType 2 diabetes030204 cardiovascular system & hematologyInternal Medicine; Endocrinology Diabetes and Metabolism; Endocrinologylaw.inventionSettore MED/13 - EndocrinologiaGlibenclamide0302 clinical medicineRandomized controlled triallawGLYCEMIC CONTROLGliclazideInternal medicinediabetes and metabolismRISKeducation.field_of_studydiabetesIncidenceInternal medicine; endocrinology diabetes and metabolism; endocrinologyMiddle AgedINSULINMetforminMetforminTreatment OutcomeEditorialsulphonylureasCardiovascular DiseasesCombinationDrug Therapy CombinationFemaleType 2medicine.drugmedicine.medical_specialtyPopulation030209 endocrinology & metabolismAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Drug Therapy Combination; Female; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment OutcomeCardiovascular events03 medical and health sciencesendocrinologyGLUCOSE-LOWERING DRUGSDrug TherapyInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentssulfonylureaseducationTOSCA.ITAgedPioglitazonebusiness.industryMORTALITYnutritional and metabolic diseasesInsulin resistancemedicine.diseaseSurgeryGlimepirideSulfonylurea CompoundsDiabetes Mellitus Type 2Diabetes Mellitus; Pioglitazone; Insulin resistanceThiazolidinedionesbusinessFOLLOW-UPPioglitazone
researchProduct

Segno e immagine

2010

Segno ImmagineSettore M-FIL/04 - Estetica
researchProduct